Bone integrity and bone metastases in breast cancer

Current Oncology Reports

Volumn 8, Issue 1, 2006, Pages 22-28

  Van Poznak, Catherine ^a   Nadal, Cristina ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID RE 188; FLUORODEOXYGLUCOSE; GONADORELIN DERIVATIVE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; LEUPRORELIN; LEXIDRONAM SAMARIUM SM 153; MONOCLONAL ANTIBODY; PAMIDRONIC ACID; RADIOISOTOPE; RADIUM 223; RHENIUM 188; RISEDRONIC ACID; STRONTIUM 89; TAMOXIFEN; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BEHAVIOR MODIFICATION; BONE BIOPSY; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE SCINTISCANNING; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE MARKER; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; INCIDENCE; JAW DISEASE; KYPHOPLASTY; MONOTHERAPY; MORBIDITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSYNTHESIS; PATIENT CARE; PERCUTANEOUS VERTEBROPLASTY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD COMPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; OSTEOPOROSIS;

EID: 31544464624     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0005-9     Document Type: Review

References (49)

1. Body JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003, 97(3 Suppl):859-865.
2. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
3. NIH consensus development panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001, 285:785-795.
4. Raisz LG: Clinical practice: screening for osteoporosis. N Engl J Med 2005, 353:164-171.
5. Dawson-Hughes B, Bonner FJ Jr, Gold DT, et al. (Development Committee): Physician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation; 2003. http://www.nof.org.
6. American Association of Clinical Endocrinologists (AACE): Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003, 9:544-564.
7. Nelson HD, Helfand M, Woolf SH, et al.: Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:529-541.
8. Miller PD, Barlas S, Brenneman SK, et al.: Approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004, 164:1113-1120.
9. Siris ES, Chen Y-T, Abbot TA, et al.: Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004, 164:1108-1112.
10. Schousboe JT, Nyman JA, Kane RL, Ensrud KE: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005, 142:734-741.
11. Hoff AO, Gagel RF: Osteoporosis in breast and prostate cancer survivors. Oncology (Huntington) 2005, 19:651-658.
12. Creep NC, Giuliano AE, Hansen NM, et al.: The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 2003, 114:653-659.
13. Chen Z, Maricic M, Bassford TL, et al.: Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:552-558.
14. Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women With hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
15. Ramaswamy B, Shapiro CL: Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003, 30:763-775.
16. ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
17. Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and the bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
18. Brufsky A, Harker W, Beck J, et al.: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial [abstract 533]. Proc ASCO 2005, 23:12s.
19. Gnant M, Jakesz R, Mlineritsch B, et al.: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12) [abstract 6]. Breast Cancer Res Treat 2004, 88(Suppl1):S8-S9.
20. Garnero P, Srnay-Rendu E, Claustrat B, et al.: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res, 2000, 15:1526-1536.
21. Rosen CJ: Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005, 353:595-603.
22. O'Regan RM, Gajdos C, Dardes RC, et al.: Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002, 94:274-283.
23. Zujewski J, Eng-Wong J, Reynolds J, et al.: A phase 2 trial of raloxifene in premenopausal women at high risk for developing invasive breast cancer. Breast Cancer Res Treat, 2002, 76(Suppl): abstract 417.
24. Black DM, Bilezikian JP, Ensrud KE, et al.: PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
25. Cosman F, Nieves J, Zion M, et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
26. Van Poznak C, Sauter S: Clinical management of osteoporosis in women with a history of breast cancer. Cancer 2005, 104:443-456.
27. Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
28. Ruggiero SL, Mehortra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaw associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
29. Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following recurrence from breast cancer. Br J Cancer, 1998, 77:336-340.
30. Mirels H: Metastatic disease in long bones: a proposed scoring system for diagnosis impending pathological fracture. Clin Orthop Rel Res 1989, 249:256-261.
31. Hipp JA, Springfield DS, Hayes WC: Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop 1995, 312:120-135.
32. Lipton A: Management of bone metastases in breast cancer. Curr Treat Opt Oncol 2005, 6:161-171.
33. Body JJ, Diel IJ, Lichinitzer M, et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004, 90:1133-1137.
34. Body JJ, Diel IJ, Lichinitser MR, et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003, 14:1399-1405.
35. Durie BGM, Woo S-B, Maerevoet D, et al.: Osteonecrosis of the jaw and bisphosphonates [correspondence]. N Engl J Med 2005, 353:99-102.
36. Van Poznak CH, Estilo CL, Sauter NP, et al.: Osteonecrosis of the jaw in patients with metastatic breast cancer [abstract]. Breast Cancer Res Treat 2004, 88 (Suppl 1): S131:3057.
37. Patchell PA, Tibbs WF, Regine R, et al.: A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis [abstract 2]. Proc ASCO 2003, 22:2.
38. Chow E: Pain and structural effects of external beam radiotherapy. Cancer Treat Rev 2005, 31(Suppl 1):S20.
39. Coleman RE, Major P, Lipton A, et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:1-11.
40. Lipton A, Costa L, Ali SM, et al.: Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001, 27:181-185.
41. Ali SM, Demers LM, Leitzel K, et al.: Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004, 15:455-459.
42. Brown JE, Cook RJ, Major P, et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
43. Vinholes J, Coleman R, Eastell R: Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996, 22:289-331.
44. Jaschke A, Bastert G, Solomayer EF, et al.: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a longtime follow-up [abstract]. Proc ASCO (Post-Meeting Edition) J Clin Oncol 2004, 22(14S):529.
45. Powles T, McCloskey E, Kurkilahti M: Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]. Proc ASCO (Post-Meeting Edition) J Clin Oncol 2004, 22(14S):528.
46. Saarto T, Vehmanen L, Blomqvist C, Elomaa I: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients [abstract]. Proc ASCO (Post-Meeting Edition) J Clin Oncol 2004, 22(14S):527.
47. Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
48. Goss PE, Ingle IN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
49. Thurlimann B, Keshaviah A, Mouridsen H, et al.: BIG 1-98: Randomized, double-blind phase III study to evaluate letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract 511]. Proc ASCO 2005, 24:6S.